Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte M and Dextrose 5% is an intravenous solution that provides electrolytes and calories. Dextrose is a monosaccharide that serves as a source of calories and water for cellular metabolism. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain fluid and electrolyte balance, and acetate and gluconate act as bicarbonate precursors to correct acidosis.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
Source of water, electrolytes, and calories for parenteral nutrition,Maintenance of fluid and electrolyte balance,Correction of metabolic acidosis (via acetate/gluconate)
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous infusion; adult dose determined by fluid and electrolyte needs; typical maintenance: 100-200 m L/hour (2-3 L/day) for normovolemic patients; adjust based on serum electrolytes, glucose, and clinical status.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
Dextrose: <15 minutes (rapidly cleared from plasma); Electrolytes: No true half-life, as they are distributed and excreted according to homeostatic mechanisms.
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, providing energy. Acetate and gluconate are metabolized primarily in the liver and skeletal muscle to bicarbonate. Electrolytes are not metabolized.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Renal: 90% (as water and electrolytes); Dextrose is metabolized to CO2 and water, with negligible renal excretion of unchanged drug.
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
Minimal (<5%) for electrolytes and dextrose; not significantly bound to plasma proteins.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Electrolytes: Vd of sodium ~0.6 L/kg (total body water); Dextrose: Vd ~0.2-0.3 L/kg (extracellular fluid); overall Vd approximates 0.6 L/kg.
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Not applicable; drug is only administered intravenously (IV), so bioavailability is 100%.
Intravenous: 100% bioavailability.
Contraindicated in severe renal impairment (e GFR < 30 m L/min/1.73 m²) due to risk of potassium and magnesium accumulation; for e GFR 30-59 m L/min/1.73 m², reduce infusion rate by 50% and monitor electrolytes; no adjustment for e GFR ≥ 60 m L/min/1.73 m².
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
Child-Pugh Class A or B: no adjustment needed; Child-Pugh Class C: monitor serum magnesium and potassium closely due to reduced clearance; consider reduced infusion rate (e.g., 75% of normal) and frequent electrolyte monitoring.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Intravenous infusion; dose based on weight: infants: 100-150 m L/kg/day; children: 100-200 m L/kg/day; adjust for ongoing losses and serum glucose; not recommended for neonates due to risk of hyperkalemia; maximum infusion rate 2-5 m L/kg/hour depending on age and clinical status.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Elderly patients: use lower initial rates (e.g., 50-100 m L/hour) with careful monitoring of fluid overload, serum electrolytes, and glucose tolerance; due to age-related renal decline, consider dose reduction if e GFR < 60 m L/min/1.73 m²; avoid in patients with heart failure or significant renal impairment.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload.,Monitor serum glucose, electrolytes, and fluid status regularly.,Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis.,Do not administer simultaneously with blood through the same infusion set (risk of hemolysis) unless using a Y-type connector with proper flushing.
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Severe hyperglycemia (e.g., diabetic ketoacidosis),Hyperkalemia,Severe renal impairment with oliguria or anuria,Hypersensitivity to any component
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No specific food interactions. Dietary potassium/magnesium intake should be monitored in patients receiving this solution to avoid electrolyte imbalance. Patients with diabetes should coordinate dextrose infusion with insulin and meal timing.
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
No evidence of teratogenicity. Plasma-Lyte M and Dextrose 5% is an isotonic crystalloid solution; dextrose and electrolytes are normal physiological constituents. Fetal risk is negligible as the solution is designed to replace fluids and electrolytes. No teratogenic effects reported in animal studies or human data. Trimester-independent low risk, but use only if clearly needed.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Compatible with breastfeeding. Components (dextrose, electrolytes) are endogenous and present in breast milk. No known M/P ratio available as the solution is composed of substances normally present in milk. Excretion is not clinically relevant; no adverse effects expected.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
No specific dose adjustments required. Pregnancy induces increased plasma volume (40-50%) and glomerular filtration rate (50-85%), but crystalloid solutions like Plasma-Lyte M and Dextrose 5% are dosed based on clinical need (fluid replacement, maintenance). Monitor for hyperglycemia due to dextrose; consider lower infusion rates in gestational diabetes or preeclampsia-related fluid sensitivity.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
PLASMA-LYTE M AND DEXTROSE 5% is a balanced isotonic crystalloid containing multiple electrolytes (Na 40, K 13, Mg 3, Cl 40, acetate 16, gluconate 20 m Eq/L) with 5% dextrose. It is used for maintenance fluid therapy, particularly in pediatric or geriatric patients, or when mild potassium/magnesium supplementation is needed. The dextrose provides ~170 kcal/L and helps prevent ketosis. Avoid in patients with hyperkalemia, hypermagnesemia, or anuria. Acetate and gluconate serve as bicarbonate precursors (acetate is rapidly metabolized; gluconate slower). Monitor serum glucose in diabetics or stress states. Compatible with most IV medications; check specific compatibility.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
This intravenous solution contains sugar (dextrose) and electrolytes to maintain fluid balance and provide calories.,Tell your healthcare provider if you have diabetes, kidney problems, or heart disease.,Report any signs of fluid overload: swelling, shortness of breath, or rapid weight gain.,This solution may be given with other medications; inform your nurse of all medications you are taking.,You may experience a cold sensation at the IV site; this is usually temporary.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte M and Dextrose 5% is an intravenous solution that provides electrolytes and calories. Dextrose is a monosaccharide that serves as a source of calories and water for cellular metabolism. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain fluid and electrolyte balance, and acetate and gluconate act as bicarbonate precursors to correct acidosis.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; adult dose determined by fluid and electrolyte needs; typical maintenance: 100-200 m L/hour (2-3 L/day) for normovolemic patients; adjust based on serum electrolytes, glucose, and clinical status.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity. Plasma-Lyte M and Dextrose 5% is an isotonic crystalloid solution; dextrose and electrolytes are normal physiological constituents. Fetal risk is neg. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.